title: Hematopoietic growth factors and chemoprotectants: should we move toward a two-step process for phase I clinical trials in oncology?
authors.affiliation: Medical Oncology Department, Centre Léon Bérard, Lyon, France.
authors.forename: Y
authors.initials: Y
authors.lastname: Merrouche
authors.forename: G
authors.initials: G
authors.lastname: Catimel
authors.forename: M
authors.initials: M
authors.lastname: Clavel
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D017321:Clinical Trials, Phase I as Topic; D006331:Heart Diseases / Q000139:chemically induced / Q000517:prevention & control; D016298:Hematopoietic Cell Growth Factors / Q000627:therapeutic use*; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced / Q000517:prevention & control; D009369:Neoplasms / Q000188:drug therapy*; D009503:Neutropenia / Q000139:chemically induced / Q000517:prevention & control; D011929:Razoxane / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D016298:Hematopoietic Cell Growth Factors; D011929:Razoxane